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A quantitative LC–MS/MS method for determination of a small
molecule agonist of EphA2 in mouse plasma and brain tissue
Bo Zhong | Yaxin Li | Nethrie Idippily | Aaron Petty | Bin Su | Bingcheng Wang
Abstract
Compound 27 {1, 12‐bis[4‐(4‐amino‐6,7‐dimethoxyquinazolin‐2‐yl)piperazin‐1‐yl]
dodecane‐1,12‐dione} is a novel small molecule agonist of EphA2 receptor tyrosine
kinase. It showed much improved activity for the activation of EphA2 receptor
compared with the parental compound doxazosin. To support further pharmacological
and toxicological studies of the compound, a method using liquid chromatography and
electrospray ionization tandem mass spectrometry (LC–MS/MS) has been developed
for the quantification of this compound. Liquid–liquid extraction was used to extract
the compound from mouse plasma and brain tissue homogenate. Reverse‐phase
chromatography with gradient elution was performed to separate compound 27 from
the endogenous molecules in the matrix, followed by MS detection using positive ion
multiple reaction monitoring mode. Multiple reaction monitoring transitions m/z
387.3→290.1 and m/z 384.1→247.1 were selected for monitoring compound
27 and internal standard prazosin, respectively. The linear calibration range was
2–200ng/mL with the intra‐ and inter‐day precision and accuracy within the
acceptable range. This method was successfully applied to the quantitative
analysis of compound 27 in mouse plasma and brain tissue with different drug
administration routes.
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1 | INTRODUCTION
Erythropoietin‐producing hepatocellular receptor 2 (EphA2) is one of
the receptor tyrosine kinases overexpressed in many types of human
cancers, and the overexpression is correlated with malignant progres-
sion and poor prognosis (Li et al., 2010; McCarron, Stringer, Day, &
Boyd, 2010; Miao et al., 2009). Upon activation by its endogenous
ligand ephrin‐A1, EphA2 suppresses tumor progression, including
induction of apoptosis, inhibition of cell proliferation and suppression
of cell migration (Carles‐Kinch, Kilpatrick, Stewart, & Kinch, 2002;
Duxbury, Ito, Zinner, Ashley, & Whang, 2004; Jackson et al., 2008;
Noblitt et al., 2004). However, in the absence of ligand, EphA2
could initiate ligand‐independent activation, which actually triggers dif-
ferent signal transduction and promotes cell migration and invasion
(Astin et al., 2010; Biao‐xue, Xi‐guang, Shuan‐ying, Wei, & Zong‐juan,
2011; Li et al., 2010; McCarron et al., 2010; Miao et al., 2009).
Unfortunately, EphA2 overexpression is always accompanied by loss
of expression or mis‐localization of ephrin‐A1 in tumors. The reduced
ligand leads to more ligand‐independent activation of EphA2, which
eventually results in tumor progression (Li et al., 2010; Miao et al.,
2009; Miao & Wang, 2012; Nasreen, Khodayari, & Mohammed, 2012;
Pasquale, 2008, 2010). In vivo studies have demonstrated that EphA2
activation by systemically administered ephrin‐A1 could decrease the
tumorigenicity and invasiveness of carcinoma xenografts (Jackson
et al., 2008; Noblitt et al., 2004; Wang, 2011). As therapeutic agents,
ephrins have multiple disadvantages such as low stability and low per-
meability. Small molecules which can mimic ephrin‐A1 for activation
of EphA2 can be exploited as novel cancer therapeutics.
Previously, we identified doxazosin that could activate EphA2
and inhibit malignant behaviors of prostate cancer in vitro and in vivo
(Petty et al., 2012). As an antagonist for α1‐adrenoreceptor, doxazosin
is commonly used for treating hypertension and benign prostate
hyperplasia. However, the potency of doxazosin as an agonist of
EphA2 is not good enough for clinical application in cancer treatment.
Further structural optimization of doxazosin led to the discovery of a
new EphA2 agonist compound 27 with enhanced affinity, specificity
and potency (Petty et al., 2018). In order to investigate the compound
with in vivo animal models for its targeting effect to EphA2 and
therapeutic efficacy, a pre‐clinical pharmacokinetic study is urgently
needed. A quantitative method for determination of the concentration
of compound 27 is required to establish the pharmacokinetic profiles.
Hence, in the present study, we describe a simple and robust method
using standard LC–MS/MS for the determination of the concentration
of compound 27 in different matrices. Finally, this method was
successfully applied to the pre‐clinical pharmacokinetic study of
compound 27 in mouse plasma and brain tissue after subcutaneous
or intraperitoneal injection into mice.
2 | EXPERIMENTAL
2.1 | Materials
Compound 27 and internal standard (ISTD) prazosin were synthesized
and purified according to the published procedure (Figure 1; Petty
et al., 2018). HPLC‐grade acetonitrile and ACS‐grade ethyl acetate
were purchased from BDH chemicals (Carle Place, NY) and LC/MS‐
grade formic acid was from Fisher Scientific (Waltham, MA, USA).
Deionized water was purified using a Barnstead NANOpure® water
purification system from Thermo Scientific (Waltham, MA, USA). Six
different lots of Non Swiss Albino Mouse plasma were obtained from
Innovative Research (Novi, MI, USA).
2.2 | Preparation of stock solutions and working
solutions
The stock solutions of compound 27 and Prazosin were prepared by
dissolving the corresponding compounds in DMSO to reach a
concentration of 1mg/mL. One set of compound 27 working solutions
at 20, 50, 100, 200, 500, 1000 and 2000 ng/mL was prepared by serial
dilution of the stock solution with acetonitrile, and then used for
preparing the calibration standards. Another set of compound 27
working solutions at 10, 30, 250 and1600 ng/mL was made in a similar
way, and used for the preparation of quality control (QC) samples. The
prazosin working solution was prepared by diluting 1mg/mL stock
solution to 100 ng/mL with acetonitrile.
2.3 | Preparation of calibration standards and quality
control samples
The calibration standards were prepared by spiking 5 μL of compound
27 working solution into 45 μL blank mouse plasma (total volume
50 μL) to give the final concentration of compound 27 at 2, 5, 10,
20, 50, 100 and 200 ng/mL. The mouse blank plasma is a mixture of
six different mouse plasma samples. The QC samples were prepared
in a similar way at 1, 3, 25 and 160 ng/mL, representing lower limit
of quantification (LLOQ), low QC (LQC), middle QC (MQC) and high
QC (HQC) of compound 27 in mouse plasma, respectively. For the
brain homogenate, six different mouse brains were homogenized
together and sonicated and then centrifuged. A 5 μL aliquot of
compound 27 working solution was added to 45 μL of blank
supernatant of the brain homogenate. All of the calibration standards
and QC samples were further treated according to the sample
preparation procedure.
2.4 | Sample preparation for analysis
For unknown study samples, 45 μL sample (serum or brain homoge-
nate) was used and 5 μL acetonitrile was added to make 50 μL, which
is identical to the standard curve samples. Samples of 50 μL of mouse
plasma or brain homogenate from the calibration standards, QC
samples or test samples were mixed with 5 μL ISTD working solution
(100 ng/mL) to reach 55 μL total volume. A 500 μL aliquot of ethyl
acetate was added to the 55 μL samples, followed by vortexing for
60 s and then centrifuging at 12,000 rpm for 15min. Then 400 μL of
supernatant was collected and blow‐dried using a nitrogen blow‐
down‐dry evaporator. The dry residue was reconstituted with 200 μL
acetonitrile–water (4:1, v/v) and then subjected to LC–MS/MS
analysis.
2.5 | LC–MS/MS analysis
The Shimadzu UPLC system (Columbia, MD) consisted of a
Prominence DGU‐20A3R inline degasser, two LC‐30 AD pumps, a
SIL‐30 AC autosampler and a CBM‐20A controller. The chromato-
graphic separation was performed on a Kinetex C18 column at room
temperature (50 × 2.1mm, 1.3 μm) with a SecurityGuard ULTRA car-
tridges and UPLC in‐line filter (Phenomenex, CA, USA). An optimized
gradient of mobile phase A, water with 2% acetonitrile and 0.1%
formic acid, and mobile phase B, acetonitrile with 0.1% formic acid
at the flow rate of 0.25mL/min, was used (see Table 1).
FIGURE 1 The chemical structures of compound 27 and internal
standard (IS) prazosin
The compound 27 detection was performed on an AB Sciex
Qtrap 5500 mass spectrometer (Toronto, Canada) with positive
electrospray ionization mode. The multiple reaction monitoring
(MRM) function was used for quantification with the transitions
setting at m/z 387.3→ 290.1 for compound 27 and m/z
384.1→ 247.1 for prazosin. The optimized ion source parameters
were set as follows: ion spray voltage, 5000V; temperature, 450°C;
heating gas, nebulization gas, curtain gas, 40 psi. Compound parame-
ters were as follows: declustering potential, 141 V; entrance potential,
10 V; collision energy, 37 V for compound 27, 39 V for ISTD; collision
exit potential, 24 V for compound 27, 18 V for ISTD. Data acquisition
and quantification were performed using analyst software (version
1.6.2).
2.6 | Analytical method validation
2.6.1 | Calibration curve, sensitivity and selectivity
Calibration curves were constructed using the peak area ratio of
compound 27 to ISTD prazosin (y) vs. the concentration of com-
pound 27 (x) in the calibration standards. The weighted linear
regression was generated using 1/x as a weighting factor. The sen-
sitivity of the method was evaluated by whether the LLOQ and the
lowest concentration in a calibration curve can be quantified with
accuracy and precision within 20%. The selectivity was evaluated
by testing the presence of the interfering peak in blank plasma
samples from six different sources and blank brain tissue with
untreated mice.
2.6.2 | Matrix effect and extraction efficiency
The relative matrix effect and extraction efficiency were studied at
three QC levels: 3, 25 and 160 ng/mL. The relative matrix effect
was determined by comparing the peak area ratio of compound 27
and ISTD spiked in the blank plasma post‐extraction solution with
that in the neat solution (acetonitrile–water, 4:1, v/v). The post‐
extraction solution was prepared by blank plasma extraction and
reconstitution of dry extracts with acetonitrile–water using the proce-
dures described above. The relative extraction efficiency was deter-
mined by comparing the peak area ratio of compound 27 and ISTD
spiked in the plasma before extraction with that spiked in blank
plasma post‐extraction solution. The same procedure was repeated
for brain homogenate.
2.6.3 | Precision and accuracy
Intra‐ and inter‐assay precision and accuracy were assessed using
QC samples at three different concentrations: 3, 25, and
160 ng/mL. Intra‐assay tests were carried out with five replicates
(n = 5) for each concentration on the same day, while inter‐assay
tests were performed for each concentration in five replicates on
five days. The experimentally determined concentrations of com-
pound 27 in QC samples were compared with the theoretical spiked
values.
2.6.4 | Stability study
The stability of compound 27 in mouse plasma was evaluated by
subjecting QC samples (3 and 160 ng/mL) to the following condi-
tions: sitting at room temperature for 6 and 24 h; three freeze–thaw
TABLE 1 HPLC gradient program
Minutes B (%)
0–1 10 (isocratic)
1–4 10–90 (linear)
4–9 90 (isocratic)
9–10 10 (linear)
10–17 10 (isocratic)
Mobile phase A was 2% acetonitrile with 0.1% formic acid and mobile
phase B was 100% acetonitrile with 0.1% formic acid.
FIGURE 2 Product ion spectra of (a) compound 27 and (b) prazosin
(IS)
cycles; and at −20°C for 2months. The freeze–thaw cycle comprised
freezing for 24 h at −20°C and then thawing at room temperature for
30min.
2.7 | Pharmacokinetic studies of compound 27 in
mouse plasma and brain tissue
The animal study was approved by Case Western Reserve Univer-
sity animal care and use committee and adhered to the Guide for
the Care and Use of Laboratory Animals, 8th edition (NIH).
Three‐month‐old female mice (Charles River) were randomly
divided to 14 groups (five mice per group). The mice were treated
with the compounds or vehicle via subcutaneous injection or intra-
peritoneal injection (two sets of different treatments). At different
time points ranging from 30 min to 24 h, the mice were anesthe-
tized to perform the heart perfusion with saline, and then eutha-
nized. A 200 μL blood sample was collected from each mouse
along with brain tissue. The plasma was immediately separated by
centrifugation at 5000 rpm for 5min at the room temperature
and stored frozen at −20°C until analysis. The brain tissue were
homogenized and centrifuged at 10,000 rpm to collect the superna-
tant, and then stored frozen at −20°C until analysis. The
examination of compound 27 was performed with the developed
quantitative method.
3 | RESULTS AND DISCUSSION
3.1 | Optimization of mass spectrometric and
chromatographic conditions
In order to optimize the MS parameters for detection, 50 ng/mL of
compound 27 and 10 ng/mL of ISTD in acetonitrile–water (4:1, v/v)
were introduced into the mass spectrometer through direct infusion
at 10 μL/min. Based on the structural properties of compound 27,
the positive ionization mode was chosen to detect the signals of the
compound. The mass spectra of compound 27 and ISTD showed
mass‐to‐charge ratio at [M + 2H]2+ 387.3 and [M+H]+ 384.1,
respectively. Owing to the symmetricak structure, compound 27
had two positive charges vs. the ISTD having only one positive
charge. The corresponding product ion spectra are shown in
Figure 2. The three most abundant product ions after fragmentation
were found at m/z 290.1, 247.1 and 231.0 for compound 27 and
m/z 247.2, 231.1 and 95.1 for ISTD. The proposed structures for
the product ions of both compound 27 and ISTD are shown in
Figure 3. The MRM transitions of m/z 387.3 → 290.1 for compound
27 and m/z 384.1 → 247.1for ISTD were selected for quantification.
The other MRM transitions, m/z 387.3 → 247.1 and 387.3 → 231.0
for compound 27, 384.1 → 231.1 and 384.1 → 95.1 for ISTD,
were also monitored during LC–MS/MS analysis for the qualitative
accuracy.
FIGURE 3 The proposed structures for
product ions of compound 27 and IS
For the chromatographic separation, various linear gradients of
water and acetonitrile were tested initially. However the peak tailing
was always an issue. Considering the dimer structural properties of
compound 27, the peak tailing could be caused by the ion‐exchange
interaction between a positive charged compound 27 and the station-
ary phase silanol in a reverse‐phase HPLC column. Therefore water–
acetonitrile mobile phases with 0.1% formic acid were tested and
found to be able to eliminate the peak tailing. An optimized gradient
of water–acetonitrile mobile phases with 0.1% formic acid eluted
compound 27 at 4.22min and ISTD at 4.04min.
3.2 | Sample extraction
As a simple and fast sample preparation technique, protein precipita-
tion (PPT) has been used extensively for sample extraction. Initially,
PPT method using acetonitrile was explored to extract compound 27
from the calibration standards. The result did not show much matrix
suppression. When it was used for extraction from the calibration
standards which was spiked with 1% Twen80 or 1% Cremophor
beforehand, significant matrix effects were observed. Mobile phase
gradient adjustment cannot eliminate the effects from both
formulation agents. Since 10% Cremophor was used as the formula-
tion agent in the animal treatment, it was present in the mouse plasma
at high concentrations (>1mg/mL) at the early sampling time points,
which could make the sample signals inaccurate. In order to reduce
or eliminate the matrix effects from the formulation agents, we
resorted to liquid–liquid extraction (LLE), which provides cleaner
extracts than PPT. Considering the solubility of compound 27 in dif-
ferent organic solvents, we tested two solvents, ethyl acetate and
methyl tert‐butyl ether, for LLE. No significant matrix effects were
observed for LLE using both solvents. However ethyl acetate yielded
slightly higher extraction recovery than methyl tert‐butyl ether. There-
fore, LLE with ethyl acetate was used for plasma sample extraction in
our study. To keep it consistent, the same method was also used for
the brain sample process.
3.3 | Development of LC–MS/MS method for the
quantification of compound 27
3.3.1 | Linearity, selectivity and sensitivity
The compound calibration curve was obtained using blank plasma or
brain homogenate supernatant and seven nonblank calibration
FIGURE 4 Representative multiple reaction
monitoring (MRM) chromatography. (a) MRM
of blank mouse plasma and brain tissue; (b)
MRM of blank mouse plasma spkied with
compound 27 at LLOQ level (1 ng/mL) and IS
(10 ng/mL); and (c) MRM of blank mouse brain
tissue spiked with compound 27 at LLOQ
level (1 ng/mL) and IS (10 ng/mL)
standards at the concentrations 2, 5, 10, 20, 50, 100 and 200 ng/mL.
The peak area ratio of compound 27 to ISTD (y) vs. compound 27
concentration (x) was plotted using a weighted (1/x) linear regression.
The compound 27 calibration curves in both mouse plasma and brain
tissue were highly linear from 2 to 200 ng/mL with correlation
coefficients (r) >0.99.
The selectivity and sensitivity of method were evaluated by
analyzing blank plasma and brain homogenate and LLOQ sample
(1 ng/mL). The MRM chromatograms of blank plasma, brain homoge-
nate, LLOQ sample spiked with compound 27 and ISTD are shown in
Figure 4. No endogenous interference was observed at 4.22min for
compound 27 and 4.04min for ISTD. The chromatograph of
compound 27 at LLOQ level showed a signal–noise ratio >10.
3.3.2 | Matrix effect and recovery
The relative matrix effect and relative extraction efficiency from
mouse plasma were evaluated at three levels of concentrations: 3,
25, 160 ng/mL. As shown in Table 2, the relative matrix effects at
three concentrations are all around 110%, indicating minimal matrix
effects. The relative extraction efficiency for three concentration
levels ranged from 93 to 102%. The results indicated that the
extraction method was efficient enough to meet the requirement of
quantification. Owing to the limited blank brain homogenate sample,
the matrix effect was only evaluated at 3 ng/mL and was found to
be in the same range of plasma matrix effects (data not shown).
3.3.3 | Precision and accuracy
The intra‐ and inter‐assay precision and accuracy were assessed at
three concentration levels: 3, 25 and 160 ng/mL. As shown in
Table 3, the precision (CV) and accuracy (RE) for all of the QC plasma
samples were within 15% in the intra‐ and inter‐assays, indicating that
the precision and accuracy of this method were effective for the quan-
titative determination of drug concentration in biological matrices.
3.3.4 | Stability
The stability of compound 27 in mouse plasma was determined for
various storage conditions by measuring the concentrations of com-
pound 27 in QC Samples after storage and comparing the results with
the theoretical value. The results of stability assay are summarized in
Table 4. There was no significant degradation or loss of compound
27 in mouse plasma after storing at room temperature for 6 and
24 h, at −20°C for 30 days and after three freeze–thaw cycles.
Compound 27 was stable in mouse plasma for at least 24 h with the
recovery >90%. The recovery of compound 27 after three freeze–
thaw cycles was 87% at LQC and 92.7% at HQC levels. The long‐term
storage stability for compound 27 at −20°C for 30 days was 85.6 and
90.4% at LQC and HQC levels, respectively.
3.4 | Application to pharmacokinetic studies of
compound 27
The validated LC–MS/MS method was applied to the measurement of
compound 27 in plasma and brain tissue samples from mice after dos-
ing at different time points. A single dose of 10mg/kg compound 27 in
PBS with 10% Cremophor was administered to mice through an intra-
peritoneal (i.p.) injection or subcutaneous injection (s.c.) route. There
were two sets of plasma and brain samples collected to compare the
different drug administration routes.
TABLE 2 Relative matrix effects and extraction recovery of com-
pound 27 in mouse plasma
Compound 27
concentration (ng/mL)
Relative matrix
effects
Relative extract
efficiency
3 109.0% 92.6%
25 111.6% 99.7%
160 110.1% 101.8%
TABLE 3 Intra‐assay and inter‐assay tests for the quantification of compound 27 in mouse plasma
Intra‐assay (n = 5) Inter‐assay (n = 5)
Spiked concentration
(ng/mL)
Determined concentration
(ng/mL) ± SD
Precision
(CV, %)
Accuracy
(RE, %)
Determined concentration
(ng/mL) ± SD
Precision
(CV, %)
Accuracy
(RE, %)
3 2.64 ± 0.03 1.1 −12 2.60 ± 0.1 3.8 −13.3
25 22.4 ± 1.89 8.4 −10.4 22.6 ± 0.15 0.66 −9.6
160 149 ± 3.74 2.5 −6.9 150.6 ± 5.0 3.3 −5.9
TABLE 4 Stability test of compound 27 in mouse plasma
Storage Conditions (n = 3) Spiked concentration (ng/mL) Determined concentration (ng/mL) ± SD Recovery (%)
At room temperature for 4 h 3 2.88 ± 0.16 96
160 151 ± 5.6 94.3
At room temperature for 24 h 3 2.76 ± 0.01 92.0
160 151.3 ± 7.8 94.5
Three freeze–thaw cycles 3 2.62 ± 0.06 87.0
160 148.3 ± 4.7 92.7
Long‐term stability (at −20°C for 30 days) 3 2.57 ± 0.10 85.6
160 144.7 ± 8.5 90.4
The compound 27 concentrations in plasma and brain tissue to
time profile were obtained for both administration routes. The
maximum concentration of compound 27 in plasma was 54 ng/mL,
which was reached at 15min after dosing with i.p. injection. However
subcutaneous injection led to much higher maximum concentration of
compound 27 in plasma from 30min to 4 h after dosing (Figure 5a and
b). The different pharmacokinetic profiles suggest that compound 27
administered by different routes may undergo different levels of
phase I metabolism. Compound 27 administered by i.p. injection prob-
ably undergoes more extensive metabolism in mouse liver, leading to
lower maximum concentration and shorter half‐life in plasma. In both
administration routes, compound 27 was detected in brain tissue. The
concentration of the drug in brain tissue was about 10–20% of the
concentration in blood, suggesting that part of the drug in the blood
circulation could pass the blood–brain barrier and accumulate in brain
tissue (Figure 5c and d). Investigation of the metabolism of compound
27 could provide rational design to reduce or eliminate the phase
I metabolism of compound 27 and improve its pharmacokinetic
performance.
4 | CONCLUSION
A rapid LC–MS/MS method for the quantification of compound 27 in
mouse plasma and brain tissue was developed and validated. This
method is simple, sensitive and specific for the analysis of compound
27 in biological matrixes. It also demonstrated excellent precision,
accuracy and reproducibility for routine analysis. The LLOQ of this
method is as low as 1 ng/mL, showing an excellent signal‐to‐noise
ratio. The linearity of calibration curve is excellent over the range of
2–200 ng/mL. We have successfully applied this LC–MS/MS method
by measuring compound 27 in mouse plasma and brain tissue from a
preclinical pharmacokinetic study. This method will be further used
in pharmacokinetic studies in the future.
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